The U.S. continues to charge significantly higher prices for prescription drugs compared with similarly wealthy countries.

Sangamo Therapeutics said on Monday that partner Pfizer has terminated their hemophilia A gene therapy co-development ...

PFE's strong economic moat is threatened by upcoming patent expirations, but its oncology segment shows promising growth ...

PF-07832837 is under clinical development by Pfizer and currently in Phase I for Asthma. According to GlobalData, Phase I drugs for Asthma have a 74% phase transition success rate (PTSR) indication ...

Pfizer plans to achieve $4 billion in savings, invest in key areas like oncology and vaccines, and project double-digit EPS ...

Donald Trump’s allies have raised over $200 million to fund his inauguration, political operations, and presidential library.

Pfizer (NYSE: PFE) stock investors are curious about the valuation and prospects for the healthcare company. *Stock prices ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the ...

The pharmaceutical industry can be a tough business. Companies must innovate constantly to stay relevant because patents ...

While the New Year's tradition of drug price hikes has held firm for years, pharma companies have decidedly tamped down on ...

The pharma giant pulled out of its partnership with Sangamo, signalling unsteady waters for the latter company and the future ...

Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got ...